Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Additive effects on rat brain 5HT release of combining phentermine with dexfenfluramine

International Journal of Obesity volume 25, pages 1450–1453 (2001)Cite this article

Abstract

OBJECTIVE AND DESIGN: This study examined the effects of the anti-obesity agents, phentermine and dexfenfluramine given alone or in combination, on in vitro and in vivo 5HT release from rat brain tissue.

RESULTS: In vitro, phentermine was without effect on basal [3H]5HT efflux from hypothalamic slices whereas dexfenfluramine (10 µM) evoked a 131% increase in [3H]5HT release. In combination, the two drugs did not alter [3H]5HT release beyond that caused by dexfenfluramine alone. At pharmacologically equivalent doses, phentermine (5.7 mg/kg, i.p.) caused a rapid, modest elevation, and dexfenfluramine (3 mg/kg, i.p.) a larger but equally rapid elevation of extracellular 5HT in the microdialysates from the rat anterior hypothalamus. In combination, the increase in extracellular 5HT evoked by these drugs was not significantly greater than the sum of their individual effects.

CONCLUSIONS: This study provides evidence that phentermine's actions are not restricted to catecholamine systems and indicates that combining phentermine with dexfenfluramine results in an additive increase in neuronal 5HT release.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Finer N . Obesity. Present and future pharmacological approaches Br Med Bull 1997 53: 409–432.

    Article  CAS  Google Scholar 

  2. Samanin R, Bernasconi S, Garattini S . The effect of selective lesioning of brain catecholamine-containing neurons on the activity of various anorectics in the rat Eur J Pharmac 1975 34: 373–375.

    Article  CAS  Google Scholar 

  3. Weiser M, Frishman WH, Michaelson MD, Abdeen MA . The pharmacologic approach to the treatment of obesity J Clin Pharmac 1997 37: 453–473.

    Article  CAS  Google Scholar 

  4. Cerulli J, Lomaestro BM, Malone M . Update on the pharmacotherapy of obesity Ann Pharmacother 1998 32: 88–102.

    Article  CAS  Google Scholar 

  5. Gundlah C, Martin KF, Heal DJ, Schott J, Auerbach SB . In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents; sibutramine is a reuptake inhibitor J Pharmac Exp Ther 1997 283: 581–591.

    CAS  Google Scholar 

  6. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC . Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from D-amphetamine and d-fenfluramine Int J Obes Relat Metab Disord 1998 22 (Suppl 1): S18–S28.

    CAS  PubMed  Google Scholar 

  7. Weintraub M . Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodel intervention study Clin Pharmac Ther 1992 51: 581–646.

    Article  CAS  Google Scholar 

  8. Connolly HM, McGoon MD . Obesity drugs and the heart Curr Probl Cardiol 1999 24: 751–792.

    Article  Google Scholar 

  9. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL . Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine JAMA 2000 283: 1703–1709.

    Article  CAS  Google Scholar 

  10. Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM, Feldman JM . Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography Circulation 1995 92: 790–795.

    Article  CAS  Google Scholar 

  11. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun J-H, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW . Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine Mol Pharmac 2000 57: 75–81.

    CAS  Google Scholar 

  12. Heal DJ, Cheetham SC, Prow MR, Martin KF, Buckett WR . A comparison of the effects on central 5HT function of sibutramine hydrochloride and other weight-modifying agents Br J Pharmac 1998 125: 301–308.

    Article  CAS  Google Scholar 

  13. Shoaib M, Baumann MH, Rothman RB, Goldberg SR, Schindler CW . Behavioral and neurochemical characteristics of phentermine and fenfluramine administered separately and as a mixture in rats Psychopharmacology 1997 131: 296–306.

    Article  CAS  Google Scholar 

  14. Rothman RB, Ayestas MA, Dersch CM, Baumann MH . Aminorex, fenfluramine, and chlorphentermine and serotonin transporter substrates. Implications for primary pulmonary hypertension Circulation 1999 100: 869–875.

    Article  CAS  Google Scholar 

  15. Baumann MH, Ayestas MA, Dersch CM, Brockington A, Rice KC, Rothman RB . Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications Synapse 2000 36: 102–113.

    Article  CAS  Google Scholar 

  16. Balcioglu A, Wurtman RJ . Effects of fenfluramine and phentermine (fen-phen) on dopamine and serotonin release in rat striatum: in vivo microdialysis study in conscious animals Brain Res 1998 813: 67–72.

    Article  CAS  Google Scholar 

  17. Lancashire B, Viggers J, Prow MR, Aspley S, Martin KF, Cheetham SC, Heal DJ . Monoamine release and uptake inhibition profiles of antiobesity agents J Psychopharmac 1998 12 (Suppl A): 143P.

    Google Scholar 

  18. Matos FF, Rollema H, Basbaum AI . Characterization of monoamine release in the lateral hypothalamus of awake, freely moving rats using in vivo microdialysis Brain Res 1990 528: 39–47.

    Article  CAS  Google Scholar 

  19. Celada P, Artigas F . Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat Naunyn-Schmiedeberg's Arch Pharmac 1993 347: 583–590.

    Article  CAS  Google Scholar 

  20. Ulus IH, Maher TJ, Wurtman RJ . Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors Biochem Pharmac 2000 59: 1611–1621.

    Article  CAS  Google Scholar 

  21. Kilpatrick IC, Traut M, Heal DJ . Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release Int J Obes Relat Metab Disord 2001 25: 1454–1458.

    Article  CAS  Google Scholar 

  22. Buczko W, De Gaetano G, Garattini S . Effect of fenfluramine on 5-hydroxytryptamine uptake and release by rat blood platelets Br J Pharmac 1975 53: 563–568.

    Article  CAS  Google Scholar 

  23. Lane EL, Prow MR, Aspley S, Kilpatrick IC, Heal DJ . d-Fenfluramine releases 5HT from whole blood of rats as measured by in vitro microdialysis Br J Pharmac 2000 129: 155P.

    Google Scholar 

  24. Celada P, Martín F, Artigas F . Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue Life Sci 1994 55: 1237–1243.

    Article  CAS  Google Scholar 

  25. Rothman RB, Redmon JB, Raatz SK, Kwong CA, Swanson JE, Bantle JP . Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin Am J Cardiol 2000 85: 913–915.

    Article  CAS  Google Scholar 

  26. Leibowitz SF, Weiss GF, Shor-Posner G . Hypothalamic serotonin: pharmacological, biochemical, and behavioural analyses of its feeding-suppressive action Clin Neuropharmac 1988 11: S51–S71.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Knoll Limited, Research and Development, Nottingham, UK

    MR Prow, B Lancashire, S Aspley, DJ Heal & IC Kilpatrick

Authors
  1. MR Prow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Lancashire
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Aspley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. DJ Heal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. IC Kilpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to IC Kilpatrick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prow, M., Lancashire, B., Aspley, S. et al. Additive effects on rat brain 5HT release of combining phentermine with dexfenfluramine. Int J Obes 25, 1450–1453 (2001). https://doi.org/10.1038/sj.ijo.0801717

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0801717

Keywords

This article is cited by

Search

Advanced search

Quick links